000062019 001__ 62019
000062019 005__ 20190709135435.0
000062019 0247_ $$2doi$$a10.3389/fmicb.2017.01002
000062019 0248_ $$2sideral$$a101071
000062019 037__ $$aART-2017-101071
000062019 041__ $$aeng
000062019 100__ $$aPérez-Laguna, V.
000062019 245__ $$aBactericidal effect of photodynamic therapy, alone or in combination with mupirocin or linezolid, on Staphylococcus aureus
000062019 260__ $$c2017
000062019 5060_ $$aAccess copy available to the general public$$fUnrestricted
000062019 5203_ $$aAntibiotic treatments frequently fail due to the development of antibiotic resistance, underscoring the need for new treatment strategies. Antimicrobial photodynamic therapy (aPDT) could constitute an alternative therapy. In bacterial suspensions of Staphylococcus aureus, which is commonly implicated in cutaneous and mucosal infections, we evaluated the in vitro efficacy of aPDT, using the photosensitizing agents rose bengal (RB) or methylene blue (MB), alone or combined with the antibiotics mupirocin (MU) or linezolid (LN). RB or MB, at concentrations ranging from 0.03 to 10 µg/ml, were added to S. aureus ATCC 29213 suspensions containing > 108 cells/ml, in the absence or presence of MU or LN (1 or 10 µg/ml). Suspensions were irradiated with a white metal halide (¿ 420-700 nm) or light-emitting diode lamp (¿ 515 and ¿ 625 nm), and the number of viable bacteria quantified by counting colony-forming units (CFU) on blood agar. Addition of either antibiotic had no significant effect on the number of CFU/ml. By contrast, RB-aPDT and MB-aPDT effectively inactivated S. aureus, as evidenced by a 6 log10 reduction in bacterial growth. In the presence of MU or LN, the same 6 log10 reduction was observed in response to aPDT, but was achieved using significantly lower concentrations of the photosensitizers RB or MB. In conclusion, the combination of MU or LN and RB/MB-aPDT appears to exert a synergistic bactericidal effect against S. aureus in vitro.
000062019 536__ $$9info:eu-repo/grantAgreement/ES/MICINN/CTQ2013-48767-C3-2-R
000062019 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000062019 590__ $$a4.019$$b2017
000062019 591__ $$aMICROBIOLOGY$$b31 / 125 = 0.248$$c2017$$dQ1$$eT1
000062019 592__ $$a1.699$$b2017
000062019 593__ $$aMicrobiology (medical)$$c2017$$dQ1
000062019 593__ $$aMicrobiology$$c2017$$dQ1
000062019 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000062019 700__ $$aPérez-Artiaga, L.
000062019 700__ $$aLampaya-Pérez, V.
000062019 700__ $$aGarcía-Luque, I.
000062019 700__ $$aBallesta, S.
000062019 700__ $$aNonell, S.
000062019 700__ $$aPaz-Cristobal, M.P.
000062019 700__ $$aGilaberte, Y.
000062019 700__ $$0(orcid)0000-0001-7294-245X$$aRezusta, A.$$uUniversidad de Zaragoza
000062019 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Microbiología
000062019 773__ $$g8, MAY (2017), 1002 [9 pp]$$pFront. microbiol.$$tFRONTIERS IN MICROBIOLOGY$$x1664-302X
000062019 8564_ $$s2923649$$uhttps://zaguan.unizar.es/record/62019/files/texto_completo.pdf$$yVersión publicada
000062019 8564_ $$s11448$$uhttps://zaguan.unizar.es/record/62019/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000062019 909CO $$ooai:zaguan.unizar.es:62019$$particulos$$pdriver
000062019 951__ $$a2019-07-09-11:33:31
000062019 980__ $$aARTICLE